American Heart Association Journal, Circulation, Publishes New Peer-Reviewed
Study Involving Protandim(R)
Study Concludes that Protandim Preserved Heart Function and Demonstrated
Strong Cardioprotective Effects in an Animal Model of Lung Disease
SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- LifeVantage Corporation (OTC
Bulletin Board: LFVN), announced that in a peer-reviewed manuscript published
in the prestigious American Heart Association journal Circulation, Dr. Norbert
Voelkel and researchers at Virginia Commonwealth University (VCU),
demonstrated the ability of Protandim, the Company's patented dietary
supplement composed of five highly synergistic "indirect antioxidants", to
protect the heart in a laboratory model of pulmonary hypertension in rats.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090930/LIFEVANTAGELOGO)
Pulmonary hypertension is a health condition characterized by high blood
pressure in the circulation between the heart and lungs and can result in
death due to right heart failure. In this study, pulmonary hypertension was
induced in the animals through a drug and by creating an oxygen-poor
environment (hypoxia). Animals pre-treated with Protandim experienced strong
cardioprotective effects. Protandim was shown to protect the heart by
increasing the expression of protective genes and by preventing the formation
of scar tissue, or fibrosis, in the heart. The study showed that Protandim
also prevented capillary loss in the heart muscle of the animals, preserving
right heart function despite the continuing stress of pressure overload.
Protandim also prevented the death of heart cells and significantly lowered
osteopontin (OPN-1) levels by more than 50%. Osteopontin is a factor that
leads to scar tissue formation, a cause of heart failure. The researchers in
this study described the ability of Protandim to effectively activate the
transcription factor Nrf2, a signal to the cell's DNA to increase expression
of a network of antioxidant, anti-inflammatory, and anti-fibrotic genes.
"We are encouraged by the results of this study, which was independently
funded and independently conducted by Dr. Voelkel and his colleagues at VCU,"
stated David Brown, President & CEO of LifeVantage. "These results illustrate
the unique antioxidant, anti-inflammatory, and anti-fibrotic properties of
Protandim. Scientists have long known of the involvement of oxidative stress
in disease processes, and this study is a significant example of how oxidative
stress affects susceptibility to right heart failure in animals. Although it
would be premature to conclude that similar benefits would be seen in humans,
these remarkable results open the door to the possibility of future research
on pulmonary hypertension and Protandim in humans."
The study entitled "Chronic pulmonary artery pressure elevation is
insufficient to explain right heart failure" was authored by Harm Bogaard,
Ramesh Natarajan, Scott C. Henderson, Carlin Long, Donatas Kraskauskas, Lisa
Smithson, Ramzi Ockaili, Joe M. McCord, and Norbert Voelkel was published
online, with a print version to follow.
About Protandim
Protandim is a clinically proven supplement that provides substantial benefits
for healthy aging. This patented indirect antioxidant therapy works in a very
different way than conventional foods such as red wine, oranges, blueberries
or other popular antioxidant supplements. Unlike those types of products that
have proven to be largely ineffective in reducing oxidative stress caused by
free radicals, Protandim is an indirect antioxidant therapy, which stimulates
the body's production of its own powerful antioxidant enzymes. Protandim works
at the cellular level, triggering cells to naturally increase production of
protective antioxidant enzymes such as superoxide dismutase (SOD), catalase,
and glutathione synthase.
A peer-reviewed human clinical study showed that after Protandim was taken for
30 consecutive days, important biochemical markers of aging were decreased by
an average of 40%. The study also reported that these markers of aging were
reduced in the subjects taking Protandim to the level of a typical 20 year
old. Protandim is currently the subject of approximately 20 scientific studies
at universities and research facilities. The nature and stages of the studies
vary.
Under the Dietary Supplement Health and Education Act, Protandim is considered
a "dietary supplement" and, as with all dietary supplements, Protandim is not
intended for the prevention, diagnosis, treatment, mitigation or cure of any
disease, including pulmonary hypertension or heart disease. For more
information about Protandim, visit www.LifeVantage.com.
About LifeVantage Corporation
LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based,
nutraceutical company dedicated to helping people reach their health and
wellness goals. Founded in 2003 and based in San Diego, CA, LifeVantage
develops products, including Protandim, that deliver significant health
benefits to consumers. For more information, visit www.LifeVantage.com.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
Words and expressions reflecting optimism, satisfaction or disappointment with
current prospects, as well as words such as "believe," "hopes," "intends,"
"estimates," "expects," "projects," "plans," "anticipates" and variations
thereof, identify forward-looking statements, but their absence does not mean
that a statement is not forward-looking. Such forward-looking statements are
not guarantees of performance and the Company's actual results could differ
materially from those contained in such statements. These forward-looking
statements are based on the Company's current expectations and beliefs
concerning future events affecting the Company and involve known and unknown
risks and uncertainties that may cause the Company's actual results or
outcomes to be materially different from those anticipated and discussed
herein. These risks and uncertainties include, among others, the potential
failure or unintended negative consequences of the implementation of our
network marketing sales channel; our ability to retain independent
distributors or to attract new independent distributors on an ongoing basis;
the potential for third party and governmental actions involving our network
marketing sales channel; the potential for product liability claims against
the Company; the risk that government regulators and regulations could
adversely affect our business; future laws or regulations may hinder or
prohibit the production or sale of our existing product and any future
products; unfavorable publicity could materially hurt our business; and the
Company's ability to protect our intellectual property rights and the value of
our product. These and other risk factors are discussed in greater detail in
the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q
under the caption "Risk Factors", and in other documents filed by the Company
from time to time with the Securities and Exchange Commission. The Company
cautions investors not to place undue reliance on the forward-looking
statements contained in this document. All forward-looking statements are
based on information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after the date
of this document, except as required by law.
Investor Relations Contact:
Ioana C. Hone
(858) 312-8000 Ext. 4
SOURCE LifeVantage Corporation
investor relations, Ioana C. Hone, +1-858-312-8000, ext. 4, for LifeVantage
Corporation
